Bioscience Animal Health PCL
Bioscience Animal Health Public Company Limited manufactures and distributes pharmaceutical supplies, devices, and equipment in Thailand. The company offers bioscience products, such as antibiotics, additives, injections, mold inhibitors, water-soluble products, vaccines, hormones, and Bismix B and SD series. It also provides products for livestock and pets, as well as trading services. The compa… Read more
Bioscience Animal Health PCL (BIS) - Total Liabilities
Latest total liabilities as of September 2025: ฿463.53 Million THB
Based on the latest financial reports, Bioscience Animal Health PCL (BIS) has total liabilities worth ฿463.53 Million THB as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioscience Animal Health PCL - Total Liabilities Trend (2017–2024)
This chart illustrates how Bioscience Animal Health PCL's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioscience Animal Health PCL Competitors by Total Liabilities
The table below lists competitors of Bioscience Animal Health PCL ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Wire Products Public Company Limited
BK:TWP
|
Thailand | ฿462.44 Million |
|
Finlay Minerals Ltd
OTCQB:FYMNF
|
USA | $3.96 Million |
|
WiSA Technologies Inc
NASDAQ:WISA
|
USA | $13.99 Million |
|
Refined Metals Corp.
PINK:RFMCF
|
USA | $891.36K |
|
Biotron Limited
PINK:BITRF
|
USA | $1.16 Million |
|
Binect AG
XETRA:MA10
|
Germany | €3.31 Million |
|
SE-Education Public Company Limited
BK:SE-ED
|
Thailand | ฿1.28 Billion |
|
Evolva Holding SA
PINK:ELVAF
|
USA | $945.30K |
Liability Composition Analysis (2017–2024)
This chart breaks down Bioscience Animal Health PCL's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioscience Animal Health PCL's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioscience Animal Health PCL (2017–2024)
The table below shows the annual total liabilities of Bioscience Animal Health PCL from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ฿438.87 Million | +0.29% |
| 2023-12-31 | ฿437.59 Million | +38.22% |
| 2022-12-31 | ฿316.59 Million | -51.46% |
| 2021-12-31 | ฿652.28 Million | +8.39% |
| 2020-12-31 | ฿601.79 Million | +170.55% |
| 2019-12-31 | ฿222.43 Million | +26.33% |
| 2018-12-31 | ฿176.06 Million | -5.72% |
| 2017-12-31 | ฿186.74 Million | -- |